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-Synuclein Inhibits -Synuclein Aggregation:
A Possible Role as an Anti-Parkinsonian Factor
protein of the non-amyloid -protein (A) component of
AD amyloid (NAC) (Iwai, 2000; Masliah et al., 1996; Ueda
et al., 1993). NAC is a highly hydrophobic 35 aa domain
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University of California, San Diego fibrils (Han et al., 1995; Iwai et al., 1995). -synuclein was
La Jolla, California 92093 subsequently found to belong to a larger family of mole-
cules, including -synuclein (or phosphoneuroprotein
14) (Jakes et al., 1994; Nakajo et al., 1993), -synuclein
Summary (or breast carcinoma-specific factor) (Jia et al., 1999),
and synoretin (Surguchov et al., 1999). The -synuclein
We characterized-synuclein, the non-amyloidogenic molecule is a natively unfolded protein (Weinreb et al.,
homolog of -synuclein, as an inhibitor of aggregation 1996) that is capable of self-aggregating to form both
of-synuclein, a molecule implicated in Parkinson’s dis- oligomers and fibrillar polymers with amyloid-like char-
ease. For this, doubly transgenic mice expressing human acteristics (Hashimoto et al., 1998). Polymerization
(h)- and-synuclein were generated. In doubly trans- could occur in several stages including formation of
genic mice,-synuclein ameliorated motor deficits, neu- protofibrils, nucleation (Wood et al., 1999), and fibril for-
rodegenerative alterations, and neuronal -synuclein mation (Hashimoto et al., 1998; Serpell et al., 2000).
accumulation seen in h-synuclein transgenic mice. Conditions promoting this aggregation include: (1) muta-
Similarly, cell lines transfected with -synuclein were tions associated with familial parkinsonism (Conway et
resistant to -synuclein accumulation. h-synuclein al., 1998; Narhi et al., 1999), (2) oxidative stress mediated
was coimmunoprecipitated with h-synuclein in the by iron, cytochrome c, or copper(II) (Hashimoto et al.,
brains of doubly transgenic mice and in the double- 1998, 1999a, 1999b; Hsu et al., 2000; Paik et al., 1999;
transfected cell lines. Our results raise the possibility Souza et al., 2000), (3) binding to lipid membrane vesi-
that -synuclein might be a natural negative regulator cles (Jo et al., 2000; Perrin et al., 2000), and (4) interac-
of -synuclein aggregation and that a similar class of
tions with amyloidogenic molecules such as NAC and
endogenous factors might regulate the aggregation
A (Jensen et al., 1997; Masliah et al., 2001; Paik et al.,
state of other molecules involved in neurodegeneration.
1998; Yoshimoto et al., 1995).
Such an anti-amyloidogenic property of -synuclein
In view of evidence suggesting that -synuclein fibrilsmight also provide a novel strategy for the treatment
may initiate neurodegeneration in vivo, inhibition ofof neurodegenerative disorders.
-synuclein aggregation may represent a feasible thera-
peutic strategy in LBD and related disorders. WhileIntroduction
some factors promote -synuclein aggregation, others
might block amyloidogenesis and aggregation (Hashi-Abnormal folding and aggregation of proteins in the
moto and Masliah, 1999). Interactions among the sy-central nervous system (CNS) has been extensively ex-
nucleins could play a role in this process, becauseplored as one of the central mechanisms leading to neu-
- and -synuclein do not seed -synuclein aggregationrodegeneration in disorders such as Alzheimer’s disease
(Biere et al., 2000) and in LBD the ratio of - to(AD), Lewy body disease (LBD), Huntington’s disease
-synuclein is altered (Rockenstein et al., 2001), sug-(HD), and Creutzfeldt-Jakob disease (CJD) (Ferrigno and
gesting that a critical balance between pro- and anti-Silver, 2000; Koo et al., 1999; Ramassamy et al., 1999).
aggregation factors might be at play in disorders suchIn LBD, a common cause of dementia and parkinsonism
as LBD and AD (Masliah, 2001; Rochet et al., 2000). Inin the elderly, neuronal accumulation of misfolded
this context, we reasoned that -synuclein, the non--synuclein has been proposed to be centrally involved
amyloidogenic homolog of -synuclein that naturallyin disease pathogenesis (Hashimoto and Masliah, 1999;
lacks the NAC domain, might inhibit the abnormal accu-Trojanowski et al., 1998). Supporting this possibility, re-
mulation of -synuclein and neurodegeneration. For thiscent studies have shown that: (1) this synaptic-associ-
purpose, doubly transgenic (doubly tg) mice expressingated molecule is the most abundant component of Lewy
human (h) - and -synuclein were generated and ana-bodies (LBs) (Spillantini et al., 1997; Takeda et al., 1998;
lyzed in the rotarod and by laser scanning confocalWakabayashi et al., 1997), (2) mutations in the -synuclein
microscopy (LSCM). Additional studies directed at in-gene are associated with rare familial forms of parkin-
vestigating the interactions between - and -synucleinsonism (Kruger et al., 1998; Polymeropoulos et al., 1997),
were performed in double transfected cells lines and inand (3) -synuclein expression in transgenic (tg) mice
(Masliah et al., 2000) and Drososphila (Feany and Ben- an in vitro cell-free system. Our results raise the intri-
der, 2000) mimics several aspects of LBD. guing possibility that -synuclein may be a natural nega-
-synuclein, a 140 amino acid (aa) synaptic molecule, tive regulator of -synuclein aggregation and that a simi-
was originally identified in human brain as the precursor lar class of endogenous factors might regulate the
aggregation state of other molecules involved in neuro-
degeneration.3 Correspondence: emasliah@ucsd.edu
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Figure 1. Generation of h- and -Synuclein tg and Bigenic Mice
(A) Diagrammatic representation of the Thy1-h-synuclein construct.
(B) Diagrammatic representation of the PDGF-h-synuclein construct.
(C) Representative autoradiograph showing levels of - and -synuclein mRNA in brain tissues from nontransgenic (non-tg), h-synuclein tg
(h-syn), h-synuclein tg (h-syn), and h-synuclein/h-synuclein doubly tg mice. The leftmost lane shows signals of undigested (U) radiolabeled
riboprobes (identified on left); the other lanes contain the same riboprobes plus brain RNA samples digested with RNases. Protected mRNAs
are indicated on the right.
(D) Western blot analysis with antibodies against h- and -synuclein showed that double-tg mice expressed levels of - and -synuclein
comparable to singly tg mice. Recombinant - and -synuclein were used as positive controls.
(E) Quantitative analysis of h- and h-synuclein mRNA in brain extracts from non-tg and tg mice. Signals were quantified by PhosphorImager
analysis and expressed as probe over signal. Singly and doubly tg mice (n  3/genotype) did not significantly differ in the ratios of h- or
h-synuclein/actin (mean  SD). Overall, levels of h-synuclein were about double that of h-synuclein.
(F) Semiquantitative analysis of levels of h- and h-synuclein immunoreactivity in the cytosolic fractions of brain homogenates from non-tg and
tg mice. Levels of immunoreactivity were obtained by PhosphorImager analysis and expressed as integrated pixel intensity. Bars  mean  SD.
Results derived growth factor B chain (PDGFB) promoter (Fig-
ures 1C and 1D). When compared to singly tg mice,
doubly tg (bigenic) mice expressed similar levels ofCharacterization of h and -Synuclein
Expression in tg Mice h- and h-synuclein mRNA (Figures 1C and 1D) and
protein immunoreactivity (Figures 1E and 1F).To test the hypothesis that in vivo interactions of
-synuclein with -synuclein might ameliorate the alter-
ations associated with -synuclein accumulation in the Coexpression of h-Synuclein in h-Synuclein
tg Mice Ameliorates Motor Deficits and Reducesbrain, tg mice expressing h-synuclein under the regula-
tory control of the murine (m) Thy-1 promoter (Figure h-Synuclein Accumulation in the Brain
In order to determine if h-synuclein improved the motor1A) were generated and crossed with our highest ex-
presser h-synuclein tg mice (Figure 1B). Ribonuclease performance and reduced neuronal accumulation of
h-synuclein, rotarod and immunochemical analysesprotection assay (RPA) showed high levels of h- and
h-synuclein expression in the brains of the singly and were performed. Rotarod analysis showed that, com-
pared to non-tg littermates, singly tg h-synuclein micedoubly tg mice (Figures 1C and 1D). However, since
h-synuclein was expressed from the mThy-1 cassette, displayed the characteristic motor deficits, which were
ameliorated in doubly tg mice coexpressing h- andmRNA levels of this molecule through out the brain were
2- to 3-fold higher compared to h-synuclein, which was h-synuclein (Figure 2A). Statistical analysis showed
that the deficits in rotarod performance of h-synucleinexpressed under the regulatory control of the platelet-
-Synuclein Inhibits -Synuclein Aggregation
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Figure 2. Characterization of Motor and Neurodegenerative Alterations in h-Synuclein tg Mice Crossed with h-Synuclein tg Mice
(A) Motor assessment in the rotarod showed that 12-month-old singly tg h-synuclein mice were significantly different from bigenic mice (*p 
0.05, one-way ANOVA with post-hoc Tukey-Krammer). In contrast, doubly tg (bigenic) mice performed at levels comparable to non-tg and
singly tg h-synuclein mice. No significant differences were observed among these latter three groups (one-way ANOVA with post-hoc
Dunnett’s) (n  10 mice per group).
(B) The numbers of the anti-h-synuclein-immunoreactive neuronal inclusions in the temporal cortex were determined in 12-month-old mice.
Compared to singly tg h-synuclein mice, bigenic mice showed a significant reduction in the number of inclusion bodies (*p  0.05, one-way
ANOVA with post-hoc Tukey-Kramer).
(C) Compared to doubly tg mice, singly tg h-synuclein mice showed a 35% decrease in the area covered by TH-positive terminals in the
striatum (*p  0.05, one-way ANOVA with post-hoc Tukey-Kramer). Levels of TH immunoreactivity were comparable among the bigenic,
h-synuclein tg, and non-tg mice.
(D) Singly tg h-synuclein mice showed a significant decrease in the percent area of the neuropil covered by anti-synaptophysin-immunoreactive
terminals in the temporal cortex, compared to non-tg controls (p  0.05, one-way ANOVA with post-hoc Dunnett’s) and bigenic mice (*p 
0.05, one-way ANOVA with post-hoc Tukey-Kramer). In contrast, bigenic mice were comparable to non-tg and singly tg h-synuclein mice
(12-month-old mice; h-synuclein tg [n  10], h-synuclein tg [n  18], bigenic [n  10], non-tg [n  17]).
tg mice were significantly different when compared to tg mice (Figure 3E). In contrast, h-synuclein tg mice
showed intense -synuclein immunoreactivity in the ter-bigenic and h-synuclein tg mice (p  0.05, one-way
ANOVA with post-hoc Tukey-Kramer), as well as non- minals, while the levels in neuronal cell bodies were low
(Figure 3F).tg littermates (p  0.05, one-way ANOVA with post-hoc
Dunnett’s) (Figure 2A). No significant differences were Bigenic mice had both h- and-synuclein immunore-
active presynaptic terminals (Figures 3G and 3H); how-observed between the latter three groups.
Consistent with previous studies (Masliah et al., 2000), ever, only occasional h-synuclein immunoreactive in-
clusions were observed in the neocortex (Figures 3Ch-synuclein tg mice had abundant intraneuronal
h-synuclein immunoreactive inclusions in the neocor- and 3D), limbic system, and substantia nigra (data not
shown). Interestingly, in the bigenic mice, one of thetex (Figures 2B, 3A, and 3B). There was a statistically
significant reduction in the numbers of inclusion bodies inclusions there was colocalization of h- and -synuclein
in (Figure 3G), supporting the possibility that interactionsin the temporal cortex of bigenic mice when compared
to h-synuclein tg mice (Figures 2B, 3C, and 3D) (p  between - and -synuclein can occur in vivo. In order
to verify this possibility, cytosolic fractions from mouse0.05, one-way ANOVA with post-hoc Tukey-Kramer). No
inclusions were found in the brains of h-synuclein tg brain homogenates were immunoprecipitated with ei-
ther rabbit anti--synuclein primary antibody or preim-and non-tg mice.
Furthermore, confocal analysis of double-immunola- mune serum, followed by immunoblot analysis with anti-
h-synuclein monoclonal antibody (LB509) (Figure 4).beled sections showed that in h-synuclein tg mice there
was intense h-synuclein accumulation in neuronal cell This study showed that h-synuclein was coimmuno-
precipitated with -synuclein only in the brains of bigenicbodies and synapses in the neocortex (Figure 3E) and
limbic system and, to a lesser extent, in the substantia mice (Figure 4), supporting the contention that-synuclein
might regulate the aggregation state of -synuclein bynigra (data not shown). Only mild-synuclein immunore-
activity was detected in the terminals of h-synuclein directly binding to it.
Neuron
216
Figure 3. Neuropathological Analysis of h-Synuclein Inclusion Formation in tg Mice
All images were obtained from the temporal cortex of 12-month-old mice.
(A–D) Sections were singly labeled with the antibody against h-synuclein and imaged by light microscopy.
(E–H) Sections were double-labeled with antibodies against h-synuclein (red) and -synuclein (green) and imaged with the LSCM.
(A) Abundant anti-h-synuclein immunoreactive inclusions were observed in h-synuclein tg mice (low-power view).
(B) Higher magnification of the image in (A).
(C) Bigenic mice showed a reduction in the number of anti-h-synuclein immunoreactive inclusions.
(D) Higher magnification of the image in (C).
(E) Singly tg h-synuclein mice showed abundant anti-h-synuclein immunoreactive inclusions (arrows). The nerve terminals in the neuropil
showed low levels of -synuclein immunoreactivity (green).
(F) Singly tg h-synuclein mice showed abundant anti--synuclein immunoreactive terminals (green). Note that neuronal cell bodies did not
show -synuclein accumulation (*) and no h-synuclein immunoreactivity was observed.
(G and H) Bigenic mice showed both anti-h- (red) and -synuclein (green) immunoreactive presynaptic terminals. Occasional h-synuclein
immunoreactive inclusions were observed (arrows). Colocalization of - and -synuclein in the inclusions is seen in orange-yellow.
h-Synuclein Reduces the Neurodegenerative neurodegenerative effects promoted by h-synuclein
accumulation.Alterations in h-Synuclein tg Mice
To determine if the improved performance in the rotarod
and reduced neuronal accumulation of h-synuclein -Synuclein Coimmunoprecipitates with -Synuclein
seen in bigenic mice was associated with reduced neu- and Inhibits -Synuclein Aggregation In Vitro
rodegeneration, levels of tyrosine hydroxylase (TH) and To further investigate the interactions between h- and
synaptophysin immunoreactivity in the caudoputamen -synuclein, coimmunoprecipitation studies in transfected
region and neocortex were analyzed. As expected, com- HEK293 cells, utilizing the polyclonal anti--synuclein and
pared to non-tg mice, singly tg h-synuclein mice showed monoclonal anti--synuclein antibodies were performed.
a significant 35% decrease in dopaminergic input to the The HEK293 cells were first transfected with muriste-rone-
basal ganglia (Figure 2C) (p  0.05, one-way ANOVA inducible expression vector carrying the cDNA for wild-
with post-hoc Dunnett’s). Levels of TH immunoreactivity type h-synuclein followed by a further stable transfec-
in the caudoputamen region of the bigenic mice were tion with h-synuclein. This system was chosen because
significantly different compared to singly tg h-synuclein it has been previously shown that overexpression of
(p  0.05, one-way ANOVA with post-hoc Tukey-Kramer). wild-type h-synuclein in HEK293 cells results in cyto-
Levels of TH immunoreactivity in bigenic mice were plasmic accumulation of -synuclein (Tabrizi et al., 2000).
comparable to non-tg and h-synuclein tg mice (Figure This study showed that h-synuclein was coimmunopreci-
2C). Furthermore, singly tg h-synuclein mice showed pitated with h-synuclein, specifically in the muristerone
a significant decrease in the percent area of the neu- A-treated cells, by the anti--synuclein serum but not
ropil covered by anti-synaptophysin-immunoreactive preimmune serum (Figure 5). h-synuclein was also pre-
terminals, when compared to bigenic synuclein (p  cipitated by anti--synuclein serum in the muri-
0.05, one-way ANOVA with post-hoc Tukey-Kramer), sterone A-treated double transformants, including
h-synuclein tg and non-tg mice synuclein (p  0.05, clones 32, 39, and 312, but not in control 3v2
one-way ANOVA with post-hoc Dunnett’s) (Figure 2D). cells (Figure 5). Consistent with these findings, immuno-
Taken together, these results suggest that the anti- cytochemical analysis showed that in the muristerone
A-treated cells (not cotransfected with h-synuclein),aggregation effects of h-synuclein also ameliorate the
-Synuclein Inhibits -Synuclein Aggregation
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Figure 4. h- and -Synuclein Coimmunoprecipitates in the Brains of tg Mice
(A) Immunoprecipitation with either rabbit anti--synuclein (lanes 1, 3, 5, and 7) or pre-immune serum (lanes 2, 4, 6, and 8), followed by
immunoblot analysis with anti-h-synuclein (LB509) showed that -synuclein was coimmunoprecipitated with -synuclein only in fractions
obtained from the brains of bigenic mice (lane 3, arrow). 50% input controls are simultaneously shown (lanes 9–12).
(B) To further verify the specificity of interactions between h-and -synuclein in tg mice, cytosolic fractions of brain homogenates
from bigenic mice were subjected to immunoprecipitation with various antibodies against cytoplasmic molecules, followed by immunoblot
analysis with the LB509 monoclonal antibody against h-synuclein. The antibodies used were as follows: anti--synuclein serum (lane 1),
anti--synuclein affinity purified antibody (lane 2), anti--synuclein affinity purified antibody preadsorbed with immunized peptides (lane 3),
anti--catenin, C-18 (lane 4), anti-PI3 kinase p85, Z-8 (lane 5), anti-Bcl2, N-19 (lane 6), and anti-ubiquitin (lane 7). Note that h-synuclein was
recognized specifically by either anti--synuclein serum (lane 1) or anti--synuclein affinity purified antibody (lane 2).
there was a prominent accumulation of h-synuclein in To further confirm that h-synuclein can specifically
block h-synuclein aggregation, analysis was performedthe cytoplasm (161.5  14.8 per sq mm) (Figures 6A–
6F), while coexpression of h-synuclein in muristerone with recombinant proteins. Immunoblot analysis with an
-synuclein-specific antibody (101–124) showed that coin-A-treated h-synuclein-overexpressing cells resulted in
reduced h-synuclein accumulation (42.0  5.5 per sq cubation of h-synuclein with recombinant h-synuclein
(but not IgG) inhibited aggregation in a dose-dependentmm) (Figures 6G–6L) (p  0.05, one-way ANOVA with
post-hoc Tukey-Kramer). No inclusions were observed manner (Figure 7). More than equimolar concentrations
of h-synuclein were effective at suppressing h-in the cells transfected with h-synuclein or vector
alone. Taken together, these results support the con- synuclein aggregation, suggesting that heterodimeriza-
tion of -synuclein with -synuclein inhibited homodi-tention that - and -synuclein interact in vivo and may
form a complex in HEK293 cells. merization of -synuclein, leading to inhibition of further
Figure 5. h- and -Synuclein Coimmuno-
precipitate in Transfected Cell Lines
(A) -synuclein coimmunoprecipitates with
-synuclein in cell cultures. pIND -synuclein
(1 and 3) and pIND (v2) transfected ECR-
293 cells were treated with muristerone A (0,
1, 5 M) for 48 hr, and the cell extracts were
analyzed for the inducible expression of
-synuclein by immunoblotting using LB509.
(B) The 3 cells were further transfected with
pCEP4 with or without -synuclein cDNA.
Highly constitutive expressers of -synuclein
(32, 39, and 312) and their control
3v2 cells were analyzed by immunoblotting
using -synuclein antibody.
(C) The 39 cells treated with or without muri-
sterone A (2 M) for 48 hr were analyzed for
the interaction of - with -synuclein by coim-
munoprecipitation experiments. The cell ex-
tracts were subjected to immunoprecipitation
using either anti--synuclein serum or preim-
mune serum, followed by immmunoblotting
with LB509.
(D) Each stable transformant (32, 39, 312, and 3v2) was treated with muristerone A, and the cell extracts were subjected to coimmuno-
precipitation studies as described in (C). In (C) and (D), 20% input controls are simultaneously shown. Results showed that h-synuclein was
coimmunoprecipitated with h-synuclein, specifically in the muristerone A-treated cells, by anti--synuclein serum but not preimmune serum.
h-synuclein was also precipitated by anti--synuclein in the muristerone A-treated double-transformants, including clones 32, 39, and
312, but not in control 3v2 cells.
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Figure 6. Analysis of h- and -Synuclein
Expression in Stably Transfected Cell Lines
Both39 (-synuclein: inducible, -synuclein:
constitutive) and 3v2 (-synuclein: induc-
ible, -synuclein: no expression) cells were
grown on coverslips and incubated either in
the presence or absence of muristerone A (2
M) for 36 hr, followed by immunolabeling with
antibodies against either h- or -synuclein
and imaged with the LSCM. The panels in the
left correspond to -synuclein (green), in the
center to -synuclein (red), and in the right
to merged images.
(A–C) The 3v2 cells without muristerone A
treatment showed very mild levels of h- and
-synuclein immunoreactivity corresponding
to endogenous expression.
(D–F). The muristerone A-treated 3v2 cells
showed increased h-synuclein immunore-
activity, as well as accumulation of h-synu-
clein as small aggregates (arrows), but not
-synuclein immunoreactivity.
(G–I) In the 32 cells without muristerone A
treatment, only -synuclein, but not h-
synuclein, immunoreactivity was observed.
(J–L) Muristerone A-treated 32 cells showed
both h- and -synuclein immunoreactivity.
However, h-synuclein accumulation and im-
munoreactivity were reduced, compared to
3v2 cells (E).
Bar  10 m.
-synuclein oligomerization. Moreover, histochemical bayashi et al., 1997). The present study indicates that
and ultrastructural studies showed that -synuclein, -synuclein might play a role in regulating the aggrega-
-synuclein 1 and 2, but not -synuclein, formed fila- tion state of -synuclein, which is consistent with previ-
mentous structures reminiscent of amyloid fibrils indi- ous studies showing that synucleins form both hetero-
cating that the aggregates formed by the -synuclein dimers and homodimers in vitro (Jensen et al., 1995). In
mutants had amyloid-like properties (data not shown). addition,-synuclein has a tendency to aggregate under
These results indicate that interactions between sy- stress conditions (Hashimoto et al., 1999a) while - and
nucleins might occur in the conserved regions of the -synuclein are less prone to aggregate (Biere et al.,
molecule. 2000), indicating that these molecules have opposing
effects. Although the mechanisms by which -synuclein
might inhibit -synuclein aggregation are unclear,Discussion
several possibilities should be considered. For example,
-synuclein might directly bind to -synuclein and pre-In view of recent studies suggesting a role for abnormal
vent further aggregation, -synuclein might also facili-interactions among CNS proteins in the pathogenesis
tate interactions of -synuclein with fatty acids in theof neurodegenerative disorders such as AD and PD (Koo
membrane, favoring the  helix rather than the  pleatedet al., 1999; Masliah, 1998; Trojanowski et al., 1998), our
conformation of -synuclein (Davidson et al., 1998).results raise the intriguing possibility that interactions
Furthermore, it is possible that -synuclein might haveamong closely homologous molecules in the same fam-
antioxidant or neuroprotective properties and sinceily of peptides might regulate the state of protein aggre-
oxidative stress promotes -synuclein aggregationgation under pathological conditions. This is important,
(Hashimoto et al., 1999a; Osterova et al., 1999; Osterova-since in the brains of patients with parkinsonian syn-
Golts et al., 2000; Souza et al., 2000), then decreasingdromes -synuclein abnormally accumulates in neu-
-synuclein oxidation might prevent aggregation.ronal cell bodies and neurites, resulting in formation of
LBs (Spillantini et al., 1997; Takeda et al., 1998; Waka- Supporting the possibility that direct interaction be-
-Synuclein Inhibits -Synuclein Aggregation
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Figure 7. -Synuclein Blocks -Synuclein
Aggregation in an In Vitro Cell-free System
(A) Schematic representation of h-synuclein
mutants (1 and 2) created by PCR-based
site-directed mutagenesis.
(B) SDS-PAGE analysis of Coomasie blue
stained gels showed that wild-type -synuclein
(-syn) did not aggregate, while -synuclein
1 and 2 (-syn 1 and 2) and -synuclein
(-syn) were aggregated.
(C and D) Immunoblot analysis with anti-
h-synuclein antibody showed that coin-
cubation of recombinant h-synuclein with
h-synuclein for 20 hr inhibited aggregation
in a dose-dependent manner.
tween - and - synuclein might block aggregation, a with its capacity to operate as a negative regulator of
-synuclein aggregation and that a similar class of en-recent study showed that - and -synuclein were coim-
munoprecipitated in a transient cotransfection system dogenous factors could regulate the aggregation of
other molecules involved in neurodegeneration. Thisin murine Neuro2A cell line (Iwata et al., 2001). Although
the authors suggested an interesting possibility that an- concept is supported by previous studies in sickle cell
anemia showing that hemoglobin F decreases hemoglo-other molecule, such as elk-1, might mediate the inter-
action of - with -synuclein, it is possible that this bin S fibrillation (Noguchi et al., 1989). Intracellular poly-
merization of hemoglobin S leads to a loss of erythrocyteinteraction results from a nonspecific high tendency of
-synuclein to bind to other proteins. Although our pre- deformability and eventual morphological sickling. High
levels of hemoglobin F were associated with reducedliminary studies do not support this possibility, addi-
tional coimmunoprecipitation and yeast hybrid experi- disease severity, suggesting that small decreases in
polymer formation at intermediate levels of hemoglobinments are necessary to scorroborate the observation
that interactions between - and -synuclein are spe- F may give rise to a small decrease in anemia, but that
greater reductions in polymer formation may be neces-cific.
Our results in the bigenic mice and in in vitro systems sary to effect a significant improvement in disease se-
verity. Similarly, previous studies relevant to amyloidsupport the possibility that both of these molecules might
interact in vivo, which is also consistent with the observa- formation in AD have shown that A40 (Hasegawa et
al., 1999) might inhibit the nucleation of the more fibrillo-tion that - and -synuclein concentrate in the same com-
partment in the synapses. This may suggest that under genic A42 species. Finally, a recent study has shown
that fibrillization of m-synuclein could be inhibited bystress conditions such as the ones observed in neurode-
generative disorders (Jenner, 1996), -synuclein might h-synuclein (Rochet et al., 2000). m-synuclein was
more fibrillogenic than the wild-type or A53T mutantdisplay anti-aggregation properties that otherwise might
not be apparent under physiological conditions. If this h-synuclein, suggesting that at least one of the six
mismatched residues (five located in the C-terminal re-is indeed the case, it is possible that an imbalance in
the ratio of - to -synuclein might render -synuclein gion) between the two proteins plays a role in fibrilliza-
tion and inhibition of fibril formation.more prone to aggregate under oxidative stress condi-
tions. In support of this possibility, in LBD ratios among Taken together, these studies support the possibility
that naturally occurring molecules with close homologythe synucleins are altered in favor of an increase in
- and a decrease in -synuclein (Rockenstein et al., to molecules exhibiting amyloidogenic properties might
have the ability to regulate the state of aggregation of2001). Furthermore, levels of -synuclein mRNA in the
brain are higher than - and -synucleins supporting neuronal proteins. Such an anti-amyloidogenic property
of -synuclein might also provide a novel strategy forthe possibility that alterations in -synuclein expression
might play a role in LBD pathogenesis. the treatment of neurodegenerative disorders.
The mechanisms by which -synuclein might promote
Experimental Proceduresneuronal dysfunction leading to neurodegeneration are
under intense scrutiny. Among the possibilities pro-
Generation of h-Synuclein, -Synuclein, and Bigenic Mice
posed, recent studies suggest that intracellular accumu- For the present study, we used the highest expresser (line D)
lation of -synuclein (El-Agnaf and Irvine, 2000) leads h-synuclein tg mice expressing wild-type h-synuclein in neurons
from the PDGFB, generated as previously described (Masliah et al.,to mitochondrial dysfunction (Hsu et al., 2000), oxidative
2000) (Figure 1B). This line was selected because early on thesestress (Osterova-Golts et al., 2000; Souza et al., 2000),
mice develop intraneuronal inclusions, dopaminergic deficits, andand caspase degradation (Alves Da Costa et al., 2000)
motor impairments (Masliah et al., 2000). The mThy-1 expressionaccentuated by mutations associated with familial par-
cassette (provided by Dr. H. van der Putten, Ciba-Geigy, Bazel) was
kinsonism (Forloni et al., 2000; Kanda et al., 2000; Zhou used to generate h-synuclein tg mice. The h-synuclein cDNA
et al., 2000). These observations imply that the neuro- fragment (405 nt, Genbank # S69965) was generated by RT/PCR
from human brain mRNA, ligated into pCRII (Invitrogen, La Jolla,protective effects of -synuclein might be associated
Neuron
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CA), and sequenced for accuracy. The h-synuclein cDNA fragment from singly tg, bigenic, and non-tg mice (Masliah et al., 2000). Sec-
tions were incubated overnight at 4	C with anti-h- or -synucleinwas released from the pCRII vector and inserted into the mThy-1
expression cassette between exon 2 and 4 (Figure 1A), purified, and specific antibody (1:500), followed by biotinylated goat anti-rabbit
IgG (1:100, Vector Laboratories, Burlingame, CA), Avidin D-Horse-microinjected into one-cell embryos (C57BL/6xDBA/2 F1) according
to standard procedures. For all experiments, heterozygous h- radish peroxidase (1:200, ABC Elite, Vector), and reacted with diami-
nobenzidine tetrahydrochloride (DAB) containing 0.001% H2O2. Sec-synuclein and h-synuclein mice were crossed to generate bigenic
mice. A total of 73 mice were generated: 11 singly tg h-synuclein, tions were analyzed with the Quantimet 570C (Leica) in order to
determine the numbers of h-synuclein immunoreactive inclusions20 singly tg h-synuclein, 22 bigenic, and 20 non-tg. Genomic DNA
was extracted from tail biopsies and analyzed with PCR amplifica- in the neocortex. For each case, three sections were analyzed, and
the results were averaged and expressed as numbers per sq mm.tion (Masliah et al., 2000; Rockenstein et al., 1995).
Double-immunocytochemical analysis was performed, as previously
described (Mucke et al., 2000), to determine the relationship betweenAssessment of Locomotor Activity
Briefly, mice were analyzed for 2 days in the rotarod (San Diego h-synuclein immunolabeled inclusions and h-synuclein-immuno-
reactive neurons. 40 m thick vibratome sections were immunola-Instruments, San Diego, CA), as previously described (Masliah et
al., 2000). On the first day, mice were trained for five trials: the first beled with the polyclonal antibodies against h-synuclein (1:1000)
detected with the Tyramide Signal Amplification-Direct (Red) systemone at 10 rpm, the second at 20 rpm, and the third to the fifth at 40
rpm. On the second day, mice were tested for seven trials at 40 (1:100, NEN Life Sciences, Boston, MA) and -synuclein (1:100)
detected with the FITC-conjugated anti-rabbit secondary antibodyrpm each. Mice were placed individually on the cylinder and the
speed of rotation increased from 0 to 40 rpm over a period of 240 s. (1:75, Vector). To determine if coexpression of h-synuclein amelio-
rated the neurodegenerative alterations associated with expressionThe length of time mice remained on the rod (fall latency) was re-
corded and used as a measure of motor function. of h-synuclein, sections were also double-immunostained with
monoclonal anti-synaptophysin-Tyramide Red (1:2000, Roche Bio-
chemicals, Indianapolis, IN) and monoclonal anti-TH-FITC (1:100,Tissue Processing
For analysis of the various lines generated, mice were euthanized by Roche) (Masliah et al., 2000). For each case, sections were immuno-
labeled in duplicate and analyzed with the LSCM and NIH Imagetranscardiac saline perfusion under anesthesia with chloral hydrate,
and brains were removed and divided sagitally. For RNA or protein 1.43 software to calculate the percent area of the neuropil covered
by synaptophysin-immunoreactive terminals in the neocortex andanalysis (Masliah et al., 2000), the right hemibrain was snap-frozen
in isopentane cooled in a Histobath (Shandon Lipshaw, Pittsburgh, TH-immunoreactive terminals in the caudoputamen and substantia
nigra (Masliah et al., 2000). For each case, three sections werePA) and stored at 
70	C. For neuropathological analysis, the left
hemibrain was immersion-fixed in 4% paraformaldehyde at 4	C for analyzed, and for each section four serial optical sections (2 m
thick) were obtained. In order to confirm the specificity of the primary48 hr and serially sectioned sagitally at 40 m with the Vibratome 2000
(Leica, Deerfield, IL), as described previously (Masliah et al., 2000). antibodies, control experiments were performed where sections
were incubated overnight in the absence of primary antibody (de-
leted), with the primary antibody preadsorbed for 48 hr with 20-foldRNA Analysis
Total RNA was isolated from snap-frozen tissues using the TRI excess of the corresponding peptide or with preimmune serum (PI).
All sections were processed simultaneously under the same con-Reagent (Molecular Research Center, Cincinnati, OH). The following
32P-labeled antisense riboprobes were used to identify specific mRNAs ditions and experiments were performed twice in order to assess
the reproducibility of results. Sections were imaged with a Zeiss(protected nucleotides [GenBank accession number]): h-synuclein
(nt 210–475 [# L08850]); h-synuclein (nt 235–459 [# S69965]); and 63X (N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss, Ger-
many) with an attached MRC1024 LSCM system (Bio-Rad, Wattford,murine actin (nt 480–559 [# M18194] of mouse actin mRNA). Levels
of specific RNAs were determined by RPA, as previously described UK) (Masliah et al., 2000).
(Rockenstein et al., 1995). Briefly, 10 g of RNA hybridized to
32P-labeled antisense riboprobes was digested with 40 U/ml RNase Cell Culture, Isolation of Stable Clones, and Induction
T1 (GIBCO-BRL, Grand Island, NY) and 20 g/ml RNase A (Sigma of h- and -Synuclein Expression
Chemical Co., St. Louis, MO) in 100 l volume digestion buffer. Human -synuclein cDNA, which is derived from the NheI and SalI
RNase was then inactivated with Proteinase K/N-Laurylsarkosine fragments of pCEP4 -synuclein (Takenouchi et al., 2001), was li-
and precipitated with 4 M-guanidine thiocyanate/0.5% N-laurylsar- gated into the NheI and XbaI site of the pIND inducible expression
kosine and isopropanol. Samples were separated on 5% acryl- vector (Invitrogen, Carlsbad, CA). The pIND constructs containing
amide/8M urea TBE gels. Dried gels were exposed to Biomax film either -synuclein or no insert were transfected into EcR-293 cells,
(Kodak, Rochester, NY), and signals were quantitated with a Phos- a permanent cell line derived from HEK293 that were previously
phorImager SF (Molecular Dynamics, Sunnyvale, CA) using the Im- transfected with the regulatory vector pVgRxR (Invitrogen). Cells
ageQuant software and expressed as integrated pixel intensities were grown as a monolayer in T75 flasks in MEM with Hank’s salts,
over defined volumes. Final values were expressed as ratios of supplemented with L-glutamine and 5% fetal calf serum. Transfec-
(specific signal-background)/(actin signal-background) to correct
tion was performed using Lipofectamine according to the manufac-
for differences in RNA content/loading across samples.
turer’s instructions (GIBCO-BRL, Grand Island, NY). After isolation
of stable clones in the presence of 400 g/ml G418, stable cell lines
Western Blot Analysis
were generated from individual clones. The ability of cells to express
Levels of h- or -synuclein immunoreactivity were analyzed in brain
h-synuclein in response to induction with muristerone was as-
homogenates separated into cytosolic and particulate fractions
sessed by Western blot analysis following a 36–48 hr induction with
(Masliah et al., 2000). Twelve g of cytosolic fraction per mouse were
5 M muristerone A (Invitrogen, Carlsbad, CA). Among the high
loaded onto 10% SDS-PAGE gels, followed by transfer onto Immobilon
inducible expressers of -synuclein, one cell line (3) was furthermembranes and incubation with the anti-h- or -synuclein antibody
transfected with mammalian expression vector pCEP4 with either(1:1000). These antibodies were generated by Research Genetics,
h-synuclein cDNA (Takenouchi et al., 2001) or no insert. StableInc. (Huntsville, AL), as previously described (Masliah et al., 2000)
clones were selected in the presence of 200 g/ml Hygromycin B,and affinity purified using the AminoLink Kit (Pierce, Rockford, IL)
followed by screening for the constitutive expression of -synucleinfollowed by followed by 125I protein A. Blots were exposed to Phos-
by immunoblotting.phorImager (Molecular Dynamics) screens and analyzed with Im-
ageQuant software. Experiments were done blind-coded, repeated
Double Immunolabeling and Confocal Analysisat least once to assess reproducibility.
of h- and h-Synuclein Overexpressing Cells
Cells were seeded at subconfluence onto poly-L-lysine-coatedImmunocytochemical and Neuropathological Analysis
glass coverslips and grown either in the presence or absence of 2of Transgenic Mice
M muristerone A for 36 hr. Cells were then washed in phosphate-Immunocytochemical analysis for- and-synuclein was performed
in serially sectioned, free-floating, blind-coded vibratome sections buffered saline (PBS) and fixed for 20 min with 4% paraformalde-
-Synuclein Inhibits -Synuclein Aggregation
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hyde. The coverslips were first incubated overnight at 4	C with the was complete. Statistical analyses were carried out with the Stat-
mouse monoclonal antibody against h-synuclein (LB509; Zymed, View 5.0 program (SAS Institute Inc., Cary, NC). Differences among
South San Francisco, CA) and detected with the Tyramide Red means were assessed by one-way analysis of variance (ANOVA)
Signal Amplification-Direct (Red) system (NEN). Cells were then fur- followed, as indicated, by post-hoc Dunnett’s (for comparisons be-
ther incubated overnight with the rabbit polyclonal anti--synuclein tween control and experimental groups) or post-hoc Tukey-Kramer
antibody (1:1000) (Takenouchi et al., 2001) and detected by the FITC- (for comparisons between experimental groups) tests. Correlation
conjugated anti-rabbit secondary antibody (Vector). The coverslips studies were carried out by simple regression analysis. The null
were air dried overnight, mounted on slides with anti-fading media hypothesis was rejected at the 0.05 level.
(Vectashield, Vector), and imaged with the LSCM. Quantification of
the numbers of h-synuclein-positive inclusions in the cultured cells Acknowledgments
was performed with the Image 1.43 analysis program. Briefly, for
each condition a total of ten digitized images (each image average This work was supported by NIH grants AG5131, AG10689, and
of 0.1 sq mm) obtained from the LSCM were transfered to a personal AG18440 and by a grant from the M.J. Fox Foundation for Parkin-
Mac G3 computer and the number of cells containing h-synuclein- son’s Research.
positive inclusions was estimated. For each condition, an average
of 1000 cells were analyzed. Received February 15, 2001; revised September 5, 2001.
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